Lexicon宣布将于8月6日盘前披露二季度财报

Lexicon Pharmaceuticals to Report Second Quarter 2026
Accessibility: Skip TopNav
Consumer Products and Services News
Automobiles and Parts News
Food & Beverage News
Home Goods & Construction News
Leisure Goods News
Media & Entertainment News
Personal Care News
Retail News
Travel and Leisure News
Energy News
Alternative Energy News
Oil Gas and Coal News
Chemicals News
Banks & Financial Services News
Banking News
Closed-End Investments News
Finance and Credit Services News
Investment Banking and Brokerage Services News
Insurance News
Real Estate & REITs News
Healthcare News
Healthcare Providers News
Medical Equipment News
Medical Supplies and Services News
Biotechnology News
Pharmaceuticals News
Cannabis Producers News
Industrials and Utilities News
Aerospace and Defense News
Construction and Materials News
Utilities News
Industrials News
Metals & Mining News
Technology and Telecom News
Software News
IT Services News
Semiconductors News
Electronic Components & Equipment News
Computer Hardware News
Telecom Equipment News
Telecom Services News
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
July 30, 2026 08:30 ET
| Source:
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) --
(Nasdaq: LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday, August 6, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.
Participants can access the conference call live via webcast on the Events page of the Company’s website at
https://investors.lexpharma.com/
. Participants who wish to ask a question may
register here
to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast will be available on the Lexicon website.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit
www.lexpharma.com
.
For Media Inquiries:
Dave Belian
lexinvest@lexpharma.com
For Investor Inquiries:
Lisa DeFrancesco
Tags
Lexicon
Lexicon Pharmaceuticals
Hypertrophic Cardiomyopathy
diabetes
Sotagliflozin
GlobeNewswire
Recommended Reading
July 27, 2026 08:30 ET
|
Source:
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
Study substantially exceeded enrollment target of 500 patients Topline results anticipated in Q1 2027 THE WOODLANDS, Texas, July 27, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc....
Read More
June 03, 2026 08:00 ET
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
THE WOODLANDS, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present data from clinical studies of sotagliflozin in Type 1...